Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > Type C Meeting Timings
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(101)
•••
Comment by Quentin30on Apr 11, 2024 10:38am
97 Views
Post# 35983237

RE:RE:RE:Type C Meeting Timings

RE:RE:RE:Type C Meeting TimingsHaving to hold a Type C meeting means there are questions ONCY has that they wish addressing...

Yes, it probably is related to potential biomarkers, and whether or not FDA will accept ONCY's suggested biomarker... the text of the new release still states potential, and not CONFIRMED...

So, this Type C meeting isn't exactly the one we want to be in...as it would be quicker simply to get on with the Phase III trial design, as per their SPA issued by FDA 6 years ago...

AFTER the FDA has fed back its responses either verbally or electronically (a Type C meeting does not have to face to face), only then can they write their trial protocol, and send that for assessment.

SO, motormouth... Feedback will be due Jun 24th, and thereafter ONCY will submit its phase III trial protocol... so NO Phase III before Q4 2024.

Jeez... and I see the market has reacted accordingly to this fabulous news... down already...LOL



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities